ClinicalTrials.gg
CompletedNCT01639339BLISS-LNUpdated Mar 19, 2021Results posted

Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

A Phase 3 interventional study of Placebo plus standard therapy and Belimumab 10 mg/kg plus standard therapy in Lupus Nephritis, sponsored by Human Genome Sciences Inc., a GSK Company. Completed at 118 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-19.

Sponsored by Human Genome Sciences Inc., a GSK Company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
448
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Enrollment
4th of 100
448 · median 50
Started
2012
with 2 others
Phase 3
16 of 114
2 open now
Registered
21st of 114
by date

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 4th largest by enrollment of the 100 interventional ones that give a count, is one of 3 that started in 2012, is one of 16 in phase 3, and was the 21st registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients with active lupus nephritis.

Read the detailed description

Study participants receive standard therapy (induction and maintenance) for lupus nephritis in addition to receiving either placebo (no active medicine) or belimumab. Induction therapy starts before the first dose of study drug (belimumab or placebo). Maintenance therapy begins after completion of induction therapy and continues for the remainder of the study. Participants receive study drug throughout the entire study, during both induction and maintenance periods. The controlled period of the study is 104 weeks. The random assignment in this study is "1 to 1" which means you have an equal chance of receiving treatment with belimumab or placebo. Participants who successfully complete the 104-week study may enter into a 6-month open-label extension. All participants in the open-label extension receive belimumab.

03

Conditions studied

  • Lupus Nephritis

Keywords

  • Antibodies
  • Systemic Lupus Erythematosus
  • Autoimmune Disease
  • Glomerulonephritis
  • Belimumab
  • Lupus
  • Nephritis
  • Kidney Diseases
  • SLE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria.
  • confirmed active lupus nephritis.
  • Clinically active lupus renal disease at screening requiring /receiving induction therapy with Standard of Care medications.
  • Autoantibody-positive.

Key Exclusion Criteria:

  • Pregnant or nursing.
  • On dialysis within the past year.
  • Treatment with belimumab within the past year .
  • Receipt of induction therapy with cyclophosphamide within 3 months prior to induction therapy for the study.
  • Receipt of any B cell targeted therapy (for example, rituximab), biological agent within the past year.
  • Severe active central nervous system (CNS) lupus.
  • Required management of acute or chronic infections within the past 60 days.
  • Current drug or alcohol abuse or dependence.
  • Tested positive for (HIV), , or .
  • History of severe allergic reaction to contrast agents or biological medicines.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
448 participants (actual)

Study arms

  • Placebo comparator
    Placebo plus standard therapy

    Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.

    Biological: Placebo plus standard therapy · Drug: Standard therapy

  • Experimental
    Belimumab 10 mg/kg plus standard therapy

    Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.

    Biological: Belimumab 10 mg/kg plus standard therapy · Drug: Standard therapy

Interventions

  • BiologicalPlacebo plus standard therapy

    Placebo plus standard therapy

  • BiologicalBelimumab 10 mg/kg plus standard therapy

    Drug page: Belimumab

    Belimumab 10 mg/kg plus standard therapy

    Also known as: BENLYSTA™

  • DrugStandard therapy

    The standard therapies allowed in this study are: - High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy OR - High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy

06

What researchers measure

Primary outcomes

  1. Double-blind Period: Percentage of Participants With Primary Efficacy Renal Response (PERR) at Week 104

    PERR is defined as urinary protein creatinine ratio \<=0.7, estimated glomerular filtration rate (eGRF) was not more than 20 percent (%) below the pre-flare value or \>=60 milliliters per minute per 1.73 square meter (mL/min/1.73m\^2) and was not a treatment failure. Analysis was performed using a logistic regression model for the comparison between Belimumab and Placebo with covariates treatment group, induction regimen (CYC vs. MMF), race (Black vs. Non-Black), Baseline urine protein-creatinine ratio (uPCR), and Baseline eGFR. Modified Intent-to-treat (mITT) Population consisted of all randomized participants who received at least one dose of study treatment and were not excluded due to Good Clinical Practice (GCP) non-compliance. Percentage of participants with PERR at Week 104 has been presented.

    Time frame: Week 104

  2. Open-label Period: Number of Participants Reporting Adverse Events (AEs) and Serious AEs (SAEs)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Number of participants with AEs and SAEs have been reported.

    Time frame: From first open-label dose (Day 1) up to open-label Week 32 (8 weeks after last dose)

  3. Open-label Period: Number of Participants Reporting Adverse Events of Special Interest (AESI)

    An AESI is one of scientific and medical concern specific to the product, for which ongoing monitoring and rapid communication by investigator to sponsor can be appropriate. A summary of protocol defined AESIs include malignant neoplasms including and excluding non-melanoma skin cancer (NMSC), post-infusion systemic reactions (PISR), all infections of special interest (opportunistic infections \[OI\], Herpes Zoster \[HZ\], tuberculosis \[TB\], and sepsis), depression (including mood disorders and anxiety)/suicide/self-injury and deaths.

    Time frame: From first open-label dose (Day 1) up to open-label Week 32 (8 weeks after last dose)

Secondary outcomes

  1. Double-blind Period: Percentage of Participants With Complete Renal Response (CRR) at Week 104

    CRR is defined as urinary protein creatinine ratio \<0.5, eGRF was not more than 10% below the pre-flare value or \>=90 mL/min/1.73m\^2 and was not a treatment failure. Analysis was performed using a logistic regression model for the comparison between Belimumab and Placebo with covariates of induction regimen (CYC vs. MMF), race (Black vs. Non-Black), Baseline uPCR and Baseline eGFR. Percentage of participants with CRR at Week 104 has been presented.

    Time frame: Week 104

  2. Double-blind Period: Percentage of Participants With PERR at Week 52

    PERR is defined as urinary protein creatinine ratio \<=0.7, eGRF was not more than 20% below the pre-flare value or \>=60 mL/min/1.73m\^2 and was not a treatment failure. Analysis was performed using a logistic regression model for the comparison between Belimumab and Placebo with covariates of induction regimen (CYC vs. MMF), race (Black vs. Non-Black), uPCR, and Baseline eGFR. Percentage of participants with PERR at Week 52 has been presented.

    Time frame: Week 52

  3. Double-blind Period: Number of Participants With Time to Death or Renal Related Event

    Events are defined as the first event experienced among the following: death, progression to end stage renal disease, doubling of serum creatinine from Baseline, renal worsening or renal-related treatment failure. Participants who discontinued randomized treatment, withdrew from the study, were lost to follow-up, or had a non renal-related treatment failure were censored. Participants who completed the 104-week treatment period were censored at the Week 104 visit. Time to event is defined as event date minus treatment start date plus one. Analysis was performed using Cox proportional hazards model for the comparison between Belimumab and Placebo adjusting for induction regimen, race, Baseline uPCR and Baseline eGFR. Number of participants with time to death or renal related event up to Week 104 has been presented.

    Time frame: Up to Week 104

  4. Double-blind Period: Percentage of Participants With Ordinal Renal Response (ORR) at Week 104

    ORR is defined with respect to reproducible responses that included CRR, partial RR (PRR) and non responder. CRR is reported when uPCR was \<0.5, eGFR was not more than 10% below pre-flare GFR or within normal range and not a treatment failure. PRR is \>=50% decrease from Baseline in uPCR and one of the following: value \<1 if Baseline \<=3, or value \<3 if the Baseline was \>3, eGFR not more than 10% below Baseline GFR or within normal range and not a treatment failure and not a CRR. Non responder is reported when neither CRR nor PRR criteria was met. Percentage of participants reporting CRR, PRR and non responders at Week 104 has been presented.

    Time frame: Week 104

  5. Double-blind Period: Number of Participants Reporting On-treatment AEs and SAEs

    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Number of participants with on-treatment AEs and SAEs has been reported.

    Time frame: Up to Week 104

  6. Double-blind Period: Number of Participants Reporting AESI

    An AESI is one of scientific and medical concern specific to the product, for which ongoing monitoring and rapid communication by investigator to sponsor can be appropriate. A summary of protocol defined AESIs include malignant neoplasms including and excluding non-melanoma skin cancer (NMSC), post-infusion systemic reactions (PISR), all infections of special interest (opportunistic infections \[OI\], Herpes Zoster \[HZ\], tuberculosis \[TB\], and sepsis), depression (including mood disorders and anxiety)/suicide/self-injury and deaths. On-treatment data is displayed.

    Time frame: Up to Week 104

07

Results

Posted Jul 7, 2020

Participant flow

This study evaluated safety and efficacy of intravenous (IV) belimumab 10 mg/kg plus standard of care (SoC) compared to placebo plus SoC in adult participants with active lupus nephritis. This was a Phase 3, multi-center, multi-national study consisting of a randomized, double-blind, placebo-controlled period and an open-label extension period. The study was conducted in 21 countries.

Double-blind Period (Up to Week 104)
Participant flow — Double-blind Period (Up to Week 104)
MilestonePlacebo to Belimumab 10 mg/kgBelimumab 10 mg/kg to Belimumab 10
Started224224
Completed170186
Not completed5438
Withdrew: Withdrawal by subject2619
Withdrew: Physician decision115
Withdrew: Lost to follow-up54
Withdrew: Protocol violation02
Withdrew: Lack of efficacy21
Withdrew: Adverse event107
Open-label Period (Up to Week 28)
Participant flow — Open-label Period (Up to Week 28)
MilestonePlacebo to Belimumab 10 mg/kgBelimumab 10 mg/kg to Belimumab 10
Started123132
Completed122124
Not completed18
Withdrew: Withdrawal by subject02
Withdrew: Lost to follow-up01
Withdrew: Protocol violation01
Withdrew: Adverse event14

Outcome measures

PrimaryDouble-blind Period: Percentage of Participants With Primary Efficacy Renal Response (PERR) at Week 104

PERR is defined as urinary protein creatinine ratio \<=0.7, estimated glomerular filtration rate (eGRF) was not more than 20 percent (%) below the pre-flare value or \>=60 milliliters per minute per 1.73 square meter (mL/min/1.73m\^2) and was not a treatment failure. Analysis was performed using a logistic regression model for the comparison between Belimumab and Placebo with covariates treatment group, induction regimen (CYC vs. MMF), race (Black vs. Non-Black), Baseline urine protein-creatinine ratio (uPCR), and Baseline eGFR. Modified Intent-to-treat (mITT) Population consisted of all randomized participants who received at least one dose of study treatment and were not excluded due to Good Clinical Practice (GCP) non-compliance. Percentage of participants with PERR at Week 104 has been presented.

Time frame:
Week 104
Reported as:
Number · Percentage of participants
Double-blind Period: Percentage of Participants With Primary Efficacy Renal Response (PERR) at Week 104
Percentage of participantsPlaceboBelimumab 10 mg/kg
Double-blind Period: Percentage of Participants With Primary Efficacy Renal Response (PERR) at Week 10432.343.0
Statistical analysis
  • Placebo vs Belimumab 10 mg/kg · Regression, Logistic · p = 0.0311 (P-value was calculated using logistic regression model. Test 1 of 5 in a step-down sequential testing procedure.) · Odds ratio (or): 1.55 · 95% CI 1.04 to 2.32Treatment comparison between Belimumab 10 mg/kg and placebo using odds ratio and its corresponding 95% confidence interval has been presented.
SecondaryDouble-blind Period: Percentage of Participants With Complete Renal Response (CRR) at Week 104

CRR is defined as urinary protein creatinine ratio \<0.5, eGRF was not more than 10% below the pre-flare value or \>=90 mL/min/1.73m\^2 and was not a treatment failure. Analysis was performed using a logistic regression model for the comparison between Belimumab and Placebo with covariates of induction regimen (CYC vs. MMF), race (Black vs. Non-Black), Baseline uPCR and Baseline eGFR. Percentage of participants with CRR at Week 104 has been presented.

Time frame:
Week 104
Reported as:
Number · Percentage of participants
Double-blind Period: Percentage of Participants With Complete Renal Response (CRR) at Week 104
Percentage of participantsPlaceboBelimumab 10 mg/kg
Double-blind Period: Percentage of Participants With Complete Renal Response (CRR) at Week 10419.730.0
Statistical analysis
  • Placebo vs Belimumab 10 mg/kg · Regression, Logistic · p = 0.0167 (P-value was calculated using logistic regression model. Test 2 of 5 in a step-down sequential testing procedure.) · Odds ratio (or): 1.74 · 95% CI 1.11 to 2.74Treatment comparison between Belimumab 10 mg/kg and placebo using odds ratio and its corresponding 95% confidence interval has been presented.
SecondaryDouble-blind Period: Percentage of Participants With PERR at Week 52

PERR is defined as urinary protein creatinine ratio \<=0.7, eGRF was not more than 20% below the pre-flare value or \>=60 mL/min/1.73m\^2 and was not a treatment failure. Analysis was performed using a logistic regression model for the comparison between Belimumab and Placebo with covariates of induction regimen (CYC vs. MMF), race (Black vs. Non-Black), uPCR, and Baseline eGFR. Percentage of participants with PERR at Week 52 has been presented.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Double-blind Period: Percentage of Participants With PERR at Week 52
Percentage of participantsPlaceboBelimumab 10 mg/kg
Double-blind Period: Percentage of Participants With PERR at Week 5235.446.6
Statistical analysis
  • Placebo vs Belimumab 10 mg/kg · Regression, Logistic · p = 0.0245 (P-value was calculated using logistic regression model. Test 3 of 5 in a step-down sequential testing procedure.) · Odds ratio (or): 1.59 · 95% CI 1.06 to 2.38Treatment comparison between Belimumab 10 mg/kg and placebo using odds ratio and its corresponding 95% confidence interval has been presented.
SecondaryDouble-blind Period: Number of Participants With Time to Death or Renal Related Event

Events are defined as the first event experienced among the following: death, progression to end stage renal disease, doubling of serum creatinine from Baseline, renal worsening or renal-related treatment failure. Participants who discontinued randomized treatment, withdrew from the study, were lost to follow-up, or had a non renal-related treatment failure were censored. Participants who completed the 104-week treatment period were censored at the Week 104 visit. Time to event is defined as event date minus treatment start date plus one. Analysis was performed using Cox proportional hazards model for the comparison between Belimumab and Placebo adjusting for induction regimen, race, Baseline uPCR and Baseline eGFR. Number of participants with time to death or renal related event up to Week 104 has been presented.

Time frame:
Up to Week 104
Reported as:
Count of participants · Participants
Double-blind Period: Number of Participants With Time to Death or Renal Related Event
ParticipantsPlaceboBelimumab 10 mg/kg
Double-blind Period: Number of Participants With Time to Death or Renal Related Event6335
Statistical analysis
  • Placebo vs Belimumab 10 mg/kg · Cox proportional hazards model · p = 0.0014 (P-value was calculated using Cox proportional hazards model. Test 4 of 5 in a step-down sequential testing procedure.) · Cox proportional hazard: 0.51 · 95% CI 0.34 to 0.77Treatment comparison between Belimumab 10 mg/kg and placebo using Cox proportional hazards ratio and its corresponding 95% confidence interval has been presented.
SecondaryDouble-blind Period: Percentage of Participants With Ordinal Renal Response (ORR) at Week 104

ORR is defined with respect to reproducible responses that included CRR, partial RR (PRR) and non responder. CRR is reported when uPCR was \<0.5, eGFR was not more than 10% below pre-flare GFR or within normal range and not a treatment failure. PRR is \>=50% decrease from Baseline in uPCR and one of the following: value \<1 if Baseline \<=3, or value \<3 if the Baseline was \>3, eGFR not more than 10% below Baseline GFR or within normal range and not a treatment failure and not a CRR. Non responder is reported when neither CRR nor PRR criteria was met. Percentage of participants reporting CRR, PRR and non responders at Week 104 has been presented.

Time frame:
Week 104
Reported as:
Number · Percentage of participants
Double-blind Period: Percentage of Participants With Ordinal Renal Response (ORR) at Week 104
Percentage of participantsPlaceboBelimumab 10 mg/kg
CRR19.730.0
PRR17.017.5
Non responder63.252.5
Statistical analysis
  • Placebo vs Belimumab 10 mg/kg · Rank ANCOVA · p = 0.0096 (P-value is rank analysis of covariance model comparing Belimumab and Placebo with covariates for treatment group, induction regimen(CYC vs MMF),race(Black vs Non-black), Baseline uPCR, and eGFR. Test 5 of 5 in step-down sequential testing procedure.)
SecondaryDouble-blind Period: Number of Participants Reporting On-treatment AEs and SAEs

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Number of participants with on-treatment AEs and SAEs has been reported.

Time frame:
Up to Week 104
Reported as:
Count of participants · Participants
Double-blind Period: Number of Participants Reporting On-treatment AEs and SAEs
ParticipantsPlaceboBelimumab 10 mg/kg
Any AE211214
Any SAE6758
SecondaryDouble-blind Period: Number of Participants Reporting AESI

An AESI is one of scientific and medical concern specific to the product, for which ongoing monitoring and rapid communication by investigator to sponsor can be appropriate. A summary of protocol defined AESIs include malignant neoplasms including and excluding non-melanoma skin cancer (NMSC), post-infusion systemic reactions (PISR), all infections of special interest (opportunistic infections \[OI\], Herpes Zoster \[HZ\], tuberculosis \[TB\], and sepsis), depression (including mood disorders and anxiety)/suicide/self-injury and deaths. On-treatment data is displayed.

Time frame:
Up to Week 104
Reported as:
Count of participants · Participants
Double-blind Period: Number of Participants Reporting AESI
ParticipantsPlaceboBelimumab 10 mg/kg
Malignancies excluding NMSC02
Malignancies including NMSC03
PISR2926
All infections of special interest3430
Depression/suicide/self-injury1611
Deaths34
PrimaryOpen-label Period: Number of Participants Reporting Adverse Events (AEs) and Serious AEs (SAEs)

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Number of participants with AEs and SAEs have been reported.

Time frame:
From first open-label dose (Day 1) up to open-label Week 32 (8 weeks after last dose)
Reported as:
Count of participants · Participants
Open-label Period: Number of Participants Reporting Adverse Events (AEs) and Serious AEs (SAEs)
ParticipantsPlacebo to Belimumab 10 mg/kgBelimumab 10 mg/kg to Belimumab 10 mg/kg
Any AE7692
Any SAE510
PrimaryOpen-label Period: Number of Participants Reporting Adverse Events of Special Interest (AESI)

An AESI is one of scientific and medical concern specific to the product, for which ongoing monitoring and rapid communication by investigator to sponsor can be appropriate. A summary of protocol defined AESIs include malignant neoplasms including and excluding non-melanoma skin cancer (NMSC), post-infusion systemic reactions (PISR), all infections of special interest (opportunistic infections \[OI\], Herpes Zoster \[HZ\], tuberculosis \[TB\], and sepsis), depression (including mood disorders and anxiety)/suicide/self-injury and deaths.

Time frame:
From first open-label dose (Day 1) up to open-label Week 32 (8 weeks after last dose)
Reported as:
Count of participants · Participants
Open-label Period: Number of Participants Reporting Adverse Events of Special Interest (AESI)
ParticipantsPlacebo to Belimumab 10 mg/kgBelimumab 10 mg/kg to Belimumab 10 mg/kg
Malignancies excluding NMSC00
Malignancies including NMSC00
PISR45
All infections of special interest26
Depression/suicide/self-injury24
Deaths10

Adverse events

Collected over All-cause mortality, non-SAEs and SAEs were summarised from the start of the first treatment up to Week 104 in double-blind period and from the first open-label dose up to Week 32 (8 weeks after last dose) in open-label extension period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo5/224 (2.2%)78/224 (34.8%)191/224 (85.3%)
Belimumab 10 mg/kg6/224 (2.7%)65/224 (29%)186/224 (83%)
Placebo to Belimumab 10 mg/kg1/123 (0.8%)5/123 (4.1%)34/123 (27.6%)
Belimumab 10 mg/kg to Belimumab 10 mg/kg0/132 (0%)10/132 (7.6%)39/132 (29.5%)
Most frequent serious events
Showing 10 of 185
Most frequent serious events
EventPlaceboBelimumab 10 mg/kgPlacebo to Belimumab 10 mg/kgBelimumab 10 mg/kg to Belimumab 10 mg/kg
PneumoniaInfections and infestations10/22410/2242/1231/132
Lupus nephritisRenal and urinary disorders8/2242/2240/1230/132
AnaemiaBlood and lymphatic system disorders6/2241/2240/1230/132
GastroenteritisInfections and infestations5/2240/2240/1230/132
Acute kidney injuryRenal and urinary disorders5/2242/2240/1230/132
Herpes zosterInfections and infestations2/2244/2240/1231/132
Lung infectionInfections and infestations4/2242/2240/1230/132
Urinary tract infectionInfections and infestations2/2244/2240/1230/132
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders4/2241/2240/1230/132
CellulitisInfections and infestations3/2240/2240/1231/132
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPlaceboBelimumab 10 mg/kgPlacebo to Belimumab 10 mg/kgBelimumab 10 mg/kg to Belimumab 10 mg/kg
Upper respiratory tract infectionInfections and infestations74/22481/22414/12323/132
DiarrhoeaGastrointestinal disorders48/22445/2240/1230/132
Urinary tract infectionInfections and infestations37/22443/22410/12312/132
NasopharyngitisInfections and infestations31/22435/2248/1233/132
HeadacheNervous system disorders35/22434/2240/1230/132
ArthralgiaMusculoskeletal and connective tissue disorders32/22426/2245/1237/132
CoughRespiratory, thoracic and mediastinal disorders21/22430/2240/1230/132
NauseaGastrointestinal disorders24/22421/2240/1230/132
HypokalaemiaMetabolism and nutrition disorders20/22424/2240/1230/132
GastroenteritisInfections and infestations23/22421/2240/1230/132

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo to Belimumab 10 mg/kgBelimumab 10 mg/kg to Belimumab 10Total
Mean33.0 ± 10.6433.7 ± 10.7333.4 ± 10.68
Sex: Female, Male
Sex: Female, Male(Participants)Placebo to Belimumab 10 mg/kgBelimumab 10 mg/kg to Belimumab 10Total
Female196198394
Male282654
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo to Belimumab 10 mg/kgBelimumab 10 mg/kg to Belimumab 10Total
American Indian (AI) or Alaska Native (AN)6410
Asian-Central/South Asian Heritage (H)235
Asian-Japanese/East Asian/Southeast Asian H107112219
Mixed Asian101
Black or African American (AA)313061
White/Caucasian/European H7172143
White/Caucasian/Arabic/North African H415
Multiple-AA/African H and AI or AN and White112
Multiple-Asian and White112
08

Study locations

118 sites
  • GSK Investigational Site
    La Palma, California 90623, United States
  • GSK Investigational Site
    San Leandro, California 94578, United States
  • GSK Investigational Site
    Torrance, California 90502, United States
  • GSK Investigational Site
    Gainesville, Florida 32610, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63110, United States
  • GSK Investigational Site
    Brooklyn, New York 11203, United States
  • GSK Investigational Site
    Great Neck, New York 11021, United States
  • GSK Investigational Site
    Manhasset, New York 11030, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    New York, New York 10032, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • GSK Investigational Site
    Columbus, Ohio 43203, United States
  • GSK Investigational Site
    Bethlehem, Pennsylvania 18017, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    Charleston, South Carolina 29425, United States
  • GSK Investigational Site
    Onalaska, Wisconsin 54650, United States
  • GSK Investigational Site
    Ciudad Autonoma Buenos Aires, Buenos Aires 1425, Argentina
  • GSK Investigational Site
    San Miguel de Tucuman, Tucumán CP 4000, Argentina
  • GSK Investigational Site
    Buenos Aires, C1119ACN, Argentina
  • GSK Investigational Site
    Ciudad Autonoma Buenos Aires, C1015ABO, Argentina
  • GSK Investigational Site
    Cordoba, 5000, Argentina
  • GSK Investigational Site
    Mendoza, 5500, Argentina
  • GSK Investigational Site
    Brussels, 1090, Belgium
  • GSK Investigational Site
    Bruxelles, 1200, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Belo Horizonte, Minas Gerais 30150-320, Brazil
  • GSK Investigational Site
    Juiz de Fora, Minas Gerais 36010-570, Brazil
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 90035-903, Brazil
  • GSK Investigational Site
    Sao Jose do Rio Preto, São Paulo 15090-000, Brazil
  • GSK Investigational Site
    Sao Paulo, São Paulo 04039-901, Brazil
  • GSK Investigational Site
    Belo Horizonte, Minas Gerais, 30150-221, Brazil
  • GSK Investigational Site
    Goiania, 74110-120, Brazil
  • GSK Investigational Site
    Lajeado, 95900-000, Brazil
  • GSK Investigational Site
    Salvador, 40050-410, Brazil
  • GSK Investigational Site
    Edmonton, Alberta T6G 2B7, Canada
  • GSK Investigational Site
    Montreal, Quebec H3G 1A4, Canada
  • GSK Investigational Site
    Wuhan, Hubei 430030, China
  • GSK Investigational Site
    Changsha, Hunan 410008, China
  • GSK Investigational Site
    Nanchang, Jiangxi 330006, China
  • GSK Investigational Site
    Shenyang, Liaoning 110004, China
  • GSK Investigational Site
    Chengdu, Sichuan 610041, China
  • GSK Investigational Site
    Beijing, 100029, China
  • GSK Investigational Site
    Chongqing, 400038, China
  • GSK Investigational Site
    Fuzhou, 350005, China
  • GSK Investigational Site
    Guangzhou, 510080, China
  • GSK Investigational Site
    Nanning, 530021, China
  • GSK Investigational Site
    Shanghai, 200025, China
  • GSK Investigational Site
    Shanghai, 200040, China
  • GSK Investigational Site
    Shanghai, 200127, China
  • GSK Investigational Site
    Shenzhen, 518035, China
  • GSK Investigational Site
    Xian, China
  • GSK Investigational Site
    Bogota, Colombia
  • GSK Investigational Site
    Olomouc, 775 20, Czechia
  • GSK Investigational Site
    Praha 2, 128 08, Czechia
  • GSK Investigational Site
    Praha 2, 128 50, Czechia
  • GSK Investigational Site
    Cean Cedex 09, 14033, France
  • GSK Investigational Site
    Créteil cedex, 94010, France
  • GSK Investigational Site
    Lille Cedex, 59037, France
  • GSK Investigational Site
    Paris, 75013, France
  • GSK Investigational Site
    Strasbourg Cedex, 67091, France
  • GSK Investigational Site
    Toulouse Cedex 9, 31059, France
  • GSK Investigational Site
    Vandoeuvre-Les-Nancy, 54511, France
  • GSK Investigational Site
    Freiburg, Baden-Wuerttemberg 79106, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30625, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45122, Germany
  • GSK Investigational Site
    Muenster, Nordrhein-Westfalen 48149, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55131, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01307, Germany
  • GSK Investigational Site
    Luebeck, Schleswig-Holstein 23538, Germany
  • GSK Investigational Site
    Jena, Thueringen 07740, Germany
  • GSK Investigational Site
    Berlin, 10117, Germany
  • GSK Investigational Site
    Goettingen, 37075, Germany
  • GSK Investigational Site
    Hong Kong, Hong Kong
  • GSK Investigational Site
    Miskolc, 3526, Hungary
  • GSK Investigational Site
    Szeged, 6725, Hungary
  • GSK Investigational Site
    Busan, 49201, Korea, Republic of
  • GSK Investigational Site
    Daejeon, 301-721, Korea, Republic of
  • GSK Investigational Site
    Daejeon, 35233, Korea, Republic of
  • GSK Investigational Site
    Jeju Special Self-Governing Prov., 690-767, Korea, Republic of
  • GSK Investigational Site
    Jeonju-si, 561-712, Korea, Republic of
  • GSK Investigational Site
    Seoul, 04763, Korea, Republic of
  • GSK Investigational Site
    Seoul, 06273, Korea, Republic of
  • GSK Investigational Site
    Seoul, 06591, Korea, Republic of
  • GSK Investigational Site
    Seoul, 120-752, Korea, Republic of
  • GSK Investigational Site
    Suwon-si, Gyeonggi-do, 16499, Korea, Republic of
  • GSK Investigational Site
    Suwon, 16247, Korea, Republic of
  • GSK Investigational Site
    Guadalajara, Jalisco 45040, Mexico
  • GSK Investigational Site
    Morelia, Michoacán 58260, Mexico
  • GSK Investigational Site
    Cuernavaca, Morelos 62170, Mexico
  • GSK Investigational Site
    Mexico, 7760, Mexico
  • GSK Investigational Site
    México, D.F., 14080, Mexico
  • GSK Investigational Site
    Groningen, 9728 NT, Netherlands
  • GSK Investigational Site
    Leiden, 2333 ZA, Netherlands
  • GSK Investigational Site
    Maastricht, 6229 HX, Netherlands
  • GSK Investigational Site
    Cebu City, 6000, Philippines
  • GSK Investigational Site
    Davao City, 8000, Philippines
  • GSK Investigational Site
    Iloilo City, 5000, Philippines
  • GSK Investigational Site
    Lipa City, Batangas, 4217, Philippines
  • GSK Investigational Site
    Manila, 1000, Philippines

Showing the first 100 of 118 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Furie R, Rovin BH, Houssiau F, Contreras G, Teng YKO, Curtis P, Green Y, Okily M, Madan A, Roth DA. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study. Clin J Am Soc Nephrol. 2022 Nov;17(11):1620-1630. doi: 10.2215/CJN.02520322. Epub 2022 Oct 27. PubMed 36302567 ↗
  • Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, Ji B, Green Y, Gonzalez-Rivera T, Bass D, Gilbride J, Tang CH, Roth DA. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022 Feb;101(2):403-413. doi: 10.1016/j.kint.2021.08.027. Epub 2021 Sep 22. PubMed 34560137 ↗
  • Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth DA. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020 Sep 17;383(12):1117-1128. doi: 10.1056/NEJMoa2001180. PubMed 32937045 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2012 to primary completion in Jul 2019, 84 months.

Results were first posted in Jul 2020, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2012
First posted
Jul 12, 2012
StartActual
Jul 12, 2012
Primary completionActual
Jul 25, 2019
CompletionActual
Mar 12, 2020
Results first posted
Jul 7, 2020
Last update
Mar 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01639339
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 12, 2012
Start date
Jul 12, 2012
Primary completion
Jul 25, 2019
Completion
Mar 12, 2020
Results posted
Jul 7, 2020
Last update
Mar 19, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion